Department of Orthopaedic Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Rothman Orthopaedic Institute, New York City, New York, USA.
PM R. 2024 Sep;16(9):1023-1029. doi: 10.1002/pmrj.13139. Epub 2024 Mar 25.
Platelet-rich plasma (PRP) use in treating orthopedic conditions has increased, yet evidence of its clinical efficacy is inconsistent and limited by heterogeneity in osteoarthritis (OA) severity, PRP preparations and protocols, and clinical outcome measurement. This review aims to characterize the variations in postinjection protocols in studies assessing the clinical efficacy of PRP for knee OA.
A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search from database inception to February 2023 of CINAHL, MEDLINE, and EMBASE was conducted.
Article screening, data extraction, and risk of bias assessments were completed in duplicate by two reviewers. Primary outcomes were presence/absence and timing of the following postinjection protocol components: nonsteroidal anti-inflammatory drug (NSAID) restrictions, non-NSAID analgesic and cryotherapy use, immediate knee flexion/extension, immediate rest, activity restriction, return-to-activity guidelines, and rehabilitation protocols. A descriptive analysis was used to analyze the data. Given study heterogeneity, a meta-analysis was not performed.
A total of 187 studies were included for analysis. Half of all studies (51.9%) excluded patients due to preinjection NSAID use, most often within 5 days of blood sampling or injection. Postinjection NSAID restriction was included in 42.8% of studies, ranging from 1 to 1800 days. Few studies (19.4%) that permitted non-NSAID analgesia restricted their use prior to clinical assessments. Postinjection immediate flexion, extension, and immobilization were rarely (8.6%) mentioned. Activity restriction was included in a third of studies (35.3%), with the most frequent length of restriction being 1 day. Postinjection return-to-activity protocols were less common (20.3%), usually with a "gradual" and/or "as tolerated" recommendation. A minority of studies (16.0%) reported physical therapy protocols and the vast majority (93.3%) were home based.
Significant heterogeneity remains in post-PRP injection protocols, with unclear consensus regarding optimal recommendations and limited rationale for the protocols outlined. Further study is necessary to compare protocols directly and to determine which pre- and postinjection recommendations can result in optimal outcomes.
富血小板血浆(PRP)在治疗骨科疾病中的应用有所增加,但其实用疗效的证据并不一致,且受到骨关节炎(OA)严重程度、PRP 制剂和方案以及临床结果测量的异质性限制。本综述旨在描述评估 PRP 治疗膝骨关节炎的临床疗效的研究中注射后方案的变化。
根据系统评价和荟萃分析的首选报告项目指南进行了系统综述。对 CINAHL、MEDLINE 和 EMBASE 数据库从成立到 2023 年 2 月的文献进行了检索。
两位审查员独立完成文章筛选、数据提取和偏倚风险评估。主要结局是以下注射后方案组成部分的存在/不存在和时间:非甾体抗炎药(NSAID)限制、非 NSAID 镇痛药和冷敷使用、膝关节即刻屈伸、即刻休息、活动限制、活动恢复指南和康复方案。采用描述性分析对数据进行分析。鉴于研究的异质性,未进行荟萃分析。
共纳入 187 项研究进行分析。所有研究中有一半(51.9%)因注射前使用 NSAID 而排除患者,最常见的情况是在采血或注射后 5 天内。42.8%的研究中包含注射后 NSAID 限制,范围为 1 至 1800 天。很少有研究(19.4%)允许使用非 NSAID 镇痛药,但在临床评估前限制其使用。很少提及注射后即刻弯曲、伸展和固定(8.6%)。三分之一的研究(35.3%)包含活动限制,最常见的限制时间为 1 天。注射后恢复活动方案较少(20.3%),通常采用“逐渐”和/或“耐受”的建议。少数研究(16.0%)报告了物理治疗方案,绝大多数(93.3%)是家庭为基础的。
PRP 注射后方案仍存在显著异质性,对于最佳推荐方案尚未达成共识,并且对于概述的方案也缺乏明确的理由。需要进一步研究来直接比较方案,并确定哪些注射前和注射后的建议可以产生最佳结果。